Breast cancer isn’t just a statistic—it’s a reality knocking on our doors, and ignoring it could cost lives. While we often hear about it, the uncomfortable truth is that many of us still avoid talking about it openly. But here’s the stark reality: breast cancer isn’t someone else’s problem. It’s here, it’s personal, and the numbers demand our attention. In 2022 alone, approximately 2.3 million women worldwide were diagnosed with breast cancer, and nearly 670,000 lost their lives to it. In India, it’s become the most common cancer among women, surpassing others that once held the top spot. Every few minutes, an Indian woman receives this diagnosis, and far too many discover it only when the disease has advanced. So, why does awareness matter so deeply? Because knowledge isn’t just power—it’s survival.
First, early detection is a game-changer. When breast cancer is caught early, treatments are significantly more effective, and survival rates soar. Second, awareness shatters the walls of fear and stigma. Too often, women ignore warning signs like lumps, nipple changes, or unusual discharge out of embarrassment, fear, or uncertainty. Third, there’s a massive gap between knowing and acting. While many have heard of breast cancer, far fewer prioritize regular screenings or even know how to perform a proper self-exam.
But here’s where it gets hopeful: the fight against breast cancer is smarter than ever. It’s no longer just about mammograms. Blood tests, genetic screenings, and advanced imaging technologies are detecting issues earlier and more accurately. Treatments, too, have evolved dramatically. Personalized medicine and targeted therapies mean doctors can tailor care to individual patients, moving beyond one-size-fits-all approaches. And this is the part most people miss—a groundbreaking UK study has unveiled a blood test that can predict how advanced breast cancer patients will respond to therapy. But here’s where it gets controversial: could this test replace traditional biopsies?
Researchers from The Institute of Cancer Research, London, have developed a blood test that analyzes circulating tumor DNA (ctDNA)—genetic material shed by cancer cells into the bloodstream. Their findings, published in Clinical Cancer Research, reveal a strong link between low ctDNA levels at the start of treatment and positive treatment responses. Dr. Arun Kumar Goel, Chairman of Surgical Oncology at Andromeda Cancer Hospital, explains, ‘Measuring ctDNA over time helps clinicians assess treatment effectiveness. Decreasing levels suggest the patient is responding, while an increase indicates resistance or disease progression—often before it shows up on scans.’
However, Dr. Goel cautions, ‘Low ctDNA doesn’t guarantee a cure. Some tumors shed minimal ctDNA, or the disease may be hidden in areas like the brain. While ctDNA clearance often signals a better prognosis, relapse is still possible. It’s a risk factor, not a definitive predictor.’ This test could reduce the need for invasive biopsies in certain cases, such as tracking treatment success or detecting resistance mutations. Yet, it can’t replace biopsies entirely, as they remain crucial for initial diagnosis, tumor grading, and in-depth analysis.
So, here’s the question: As we embrace these advancements, how do we ensure they reach every woman who needs them? And could this technology widen the gap between those who have access to cutting-edge care and those who don’t? Let’s keep the conversation going—share your thoughts in the comments below.
